MktsMarkets

PharmaCyte Biotech, Inc.
NASDAQ: PMCBKey statistics
PMCB News
Stories mentioning PMCB from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Jan 31 | Q4 '25Oct 31 | Q3 '25Jul 31 | Q2 '25Apr 30 | Q1 '25Jan 31 | Q4 '24Oct 31 | Q3 '24Jul 31 | Q2 '24Apr 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 93.00 | 141.00 | 95.00 | 127.00 | 118.00 | 97.00 | 96.00 | 94.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 2,118 | 1,376 | 848.00 | 1,043 | 960.00 | 1,106 | 1,269 | 3,166 |
| Operating Income (Loss) | (2,118) | (1,376) | (848.00) | (1,043) | (960.00) | (1,106) | (1,269) | (3,166) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (1.00) | 0.00 | 0.00 | 0.00 | 0.00 | (1.00) | 0.00 | 194.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | 747.00 | (7,418) | (8,360) | 11,750 | (3,045) | (1,470) | 23,421 | 1,347 |
| Earnings Per Share (Basic) | (0.17) | (1.24) | (1.23) | 1.60 | (0.44) | (0.39) | 1.90 | 0.14 |
| Earnings Per Share (Diluted) | (0.17) | (1.24) | (1.23) | 1.60 | (0.44) | (0.39) | 1.90 | 0.14 |
| Weighted Average Shares Outstanding (Basic) | 9,263 | 6,796 | 6,796 | 7,330 | 6,960 | 7,637 | 7,866 | 9,581 |
| Weighted Average Shares Outstanding (Diluted) | 9,263 | 6,796 | 6,796 | 7,330 | 6,960 | 7,637 | 7,866 | 9,581 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About PMCB
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) is a stock listed on the Nasdaq Stock Market under the ticker symbol PMCB. It last traded at $0.4200 (Nov 9, 2026, 2:27 PM ET), up 15.3% on the day. That gives PharmaCyte Biotech a market capitalisation of $3.9M.
Over the past 52 weeks PMCB has traded between $0.3000 and $1.51.
Revenue for the quarter ended Jan 31, 2026 was $0; net income $747.0K.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Jan 31, 2026 | $0 | $747.0K |
| Oct 31, 2025 | $0 | -$7.4M |
| Jul 31, 2025 | $0 | -$8.4M |
| Apr 30, 2025 | $0 | $11.8M |
From PharmaCyte Biotech’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…